Cargando…
Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor Therapy in Three Subjects with the Cystic Fibrosis Genotype Phe508del/Unknown and Advanced Lung Disease
We evaluated the effectiveness and safety of elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) in three subjects carrying the Phe508del/unknown CFTR genotype. An ex vivo analysis on nasal epithelial cells (NEC) indicated a significant improvement of CFTR gating activity after the treatment. Three patie...
Autores principales: | Terlizzi, Vito, Colangelo, Carmela, Marsicovetere, Giovanni, D’Andria, Michele, Francalanci, Michela, Innocenti, Diletta, Masi, Eleonora, Avarello, Angelo, Taccetti, Giovanni, Amato, Felice, Comegna, Marika, Castaldo, Giuseppe, Salvatore, Donatello |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8391133/ https://www.ncbi.nlm.nih.gov/pubmed/34440351 http://dx.doi.org/10.3390/genes12081178 |
Ejemplares similares
-
Elexacaftor/tezacaftor/ivacaftor as rescue therapy in a patient with the cystic fibrosis genotype F508DEL/G1244E
por: Salvatore, Donatello, et al.
Publicado: (2021) -
Elexacaftor–Tezacaftor–Ivacaftor Therapy for Cystic Fibrosis Patients with The F508del/Unknown Genotype
por: Comegna, Marika, et al.
Publicado: (2021) -
Elexacaftor/Tezacaftor/Ivacaftor in Patients with Cystic Fibrosis Homozygous for the F508del Mutation and Advanced Lung Disease: A 48-Week Observational Study
por: Carnovale, Vincenzo, et al.
Publicado: (2022) -
Concomitant Use of Elexacaftor/Tezacaftor/Ivacaftor and Etanercept in a Cystic Fibrosis Patient with Juvenile Idiopathic Arthritis
por: Orsini, Sara Immacolata, et al.
Publicado: (2023) -
Elexacaftor/tezacaftor/ivacaftor for cystic fibrosis
Publicado: (2021)